Breaking News

Merck Acquires OncoEthix

Gains Phase I oncology candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck has acquired OncoEthix, a Swiss-based biotechnology company specializing in oncology drug development. With the acquisition, Merck gains an investigational, oral BET (bromodomain) inhibitor, OTX015, currently in Phase Ib studies for the treatment of hematological malignancies and advanced solid tumors. OncoEthix will receive an upfront payment of as much as $110 million and additional milestones of as much as $265 million based on certain clinical and regulatory achievements.   BET protein...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters